1 – 9 of 9
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy
(
- Contribution to journal › Article
-
Mark
COMBAT-MS : A Population-Based Observational Cohort Study Addressing the Benefit–Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab
(
- Contribution to journal › Article
-
Mark
A Federated Database for Obesity Research : An IMI-SOPHIA Study
(
- Contribution to journal › Article
- 2023
-
Mark
Predictors of patient-reported fatigue symptom severity in a nationwide multiple sclerosis cohort
(
- Contribution to journal › Article
- 2022
-
Mark
COVID-19 clinical outcomes and DMT of MS patients and population-based controls
(
- Contribution to journal › Article
- 2020
-
Mark
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients
(
- Contribution to journal › Article
-
Mark
Infection Risks among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
(
- Contribution to journal › Article
- 2017
-
Mark
Antibody Affinity Against 2009 A/H1N1 Influenza and Pandemrix Vaccine Nucleoproteins Differs Between Childhood Narcolepsy Patients and Controls
(
- Contribution to journal › Article
- 2014
-
Mark
A/H1N1 antibodies and TRIB2 autoantibodies in narcolepsy patients diagnosed in conjunction with the Pandemrix vaccination campaign in Sweden 2009-2010.
(
- Contribution to journal › Article